This high dose nusinersen regimen for spinal muscular atrophy includes 50mg loading doses and 28mg maintenance doses.
Zacks Investment Research on MSN
Biogen secures FDA nod for higher dose of SMA drug Spinraza
Shares of Biogen BIIB rose 2% on Monday after the company announced that the FDA approved a higher dose of its blockbuster ...
The FDA has approved a high-dose regimen of Biogen’s nusinersen (SPINRAZA) for the treatment of spinal muscular atrophy. 1 ...
The FDA has approved a higher-dose regimen of Spinraza for spinal muscular atrophy, providing a new treatment option for ...
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in ...
2d
Did FDA’s High‑Dose SPINRAZA Approval Just Shift Biogen’s (BIIB) Rare Disease Investment Narrative?
In late March 2026, Biogen announced that the U.S. FDA approved a new High Dose Regimen of SPINRAZA (nusinersen) for spinal muscular atrophy, allowing faster loading with two 50 mg doses and 28 mg ...
Spinraza (nusinersen) is a brand-name drug that’s prescribed for spinal muscular atrophy (SMA) in adults and children. Spinraza comes as a spinal injection that’s given by a healthcare professional ...
Ultomiris (ravulizumab-cwvz) is a brand-name drug prescribed for certain autoimmune conditions. Ultomiris is given as an intravenous (IV) infusion by a healthcare professional. The drug’s dosing ...
By Mariam Sunny and Kunal Das March 30 (Reuters) - The U.S. Food and Drug Administration has approved a higher dose of Biogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results